PVCT

Provectus Biopharmaceuti... (QB) Stock Price

0.0945
0.00465 (5.18%)
0.0945
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Provectus Biopharmaceuticals Inc (QB) PVCT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00465 5.18% 0.0945 16:02:05
Close Price Low Price High Price Open Price Previous Close
0.0945 0.08925 0.0945 0.0899 0.08985
Bid Price Ask Price Spread News
0.086 0.0995 0.0135 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
53 298,577 $ 0.091316 $ 27,265 337,774 0.03 - 0.13
Last Trade Time Type Quantity Stock Price Currency
15:58:35 900 $ 0.0945 USD

Provectus Biopharmaceuti... (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 36.92M 390.71M 373.78M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
23.58k $ - 0.00% - -

more financials information »

Provectus Biopharmaceuti... (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PVCT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1090.110.083050.095022533,665-0.0145-13.3%
1 Month0.05870.130.040.0817743553,7250.035860.99%
3 Months0.04250.130.040.0675934337,5180.052122.35%
6 Months0.05380.130.030.0567033331,5720.040775.65%
1 Year0.0650.130.030.0592523301,3110.029545.38%
3 Years0.02690.130.01110.0596506381,7810.0676251.3%
5 Years0.0350.130.0110.0392146831,9690.0595170.0%

Provectus Biopharmaceuti... (QB) Description

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of chemical small molecules called halogenated xanthenes. Intratumoral (aka intralesional) PV-10, the first small molecule autolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic uveal melanoma), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma) and blood cancers (e.g., acute myeloid leukemia). Topical PH-10 is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.